Research programme: antibody therapeutics - Alder Biopharmaceuticals/Merck & Co

Latest Information Update: 13 Dec 2010

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Alder Biopharmaceuticals; Schering-Plough
Developer Alder Biopharmaceuticals; Merck & Co
Class Antibodies
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Unspecified

Most Recent Events

25 Aug 2009 Preclinical development is ongoing in USA
11 Jun 2009 Alder and Schering-Plough expand collaboration to identify and develop therapeutic monoclonal antibodies in the USA
14 Dec 2005 Preclinical trials in Undefined in USA (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.